Authors
Latest:
Future Outlooks in the Treatment of R/R DLBCLShared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
Latest:
Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in CareClosing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.
Latest:
Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline SettingExpert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.
Latest:
Primary Radiation Therapy for Myeloid Sarcoma of the Porta HepatisTreating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.
Latest:
Dr. Shah on Novel Therapies for Multiple MyelomaJatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.
Latest:
Dr. Pinilla-Ibarz on the Benefit of BTK Inhibitors in CLLJavier Pinilla-Ibarz, MD, PhD, discusses the benefit of utilizing BTK inhibitors in chronic lymphocytic leukemia.
Latest:
Dr Cortés on Analyzing Outcomes With T-DXd in HER2+ Breast Cancer With Brain MetastasesJavier Cortés, MD, PhD, discusses the rationale for analyzing outcomes with trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who have brain metastases.
Latest:
Future Perspectives on the Treatment Landscape for CLLA panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.
Latest:
Dr. Zulueta on the Application of the LuCED Test for Lung CancerJavier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.
Latest:
Dr. Ciezki on Common Advanced Disease Sites in PatientsJay Ciezki, MD, Department of Radiation Oncology, Cleveland Clinic, discusses an analysis of patients with various malignancies who commonly presented with advanced disease.
Latest:
Dr. Raman on Hematuria in Urothelial CancerJay D. Raman, MD, professor of Surgery and chief of the Division of Urology at Penn State Milton S. Hershey Medical Center, discusses hematuria in patients with urothelial carcinoma.
Latest:
Identifying Factors That Limit Access to Prostate Cancer TherapyJay H. Fowke, PhD, MPH, MS, chief, Division of Epidemiology, professor of preventive medicine, University of Tennessee Health Science Center, discusses factors that can lead to disparity in access to prostate cancer therapy.
Latest:
Dr. Yang on the Current Treatment Landscape in MCLJay Yang, MD, discusses the current treatment landscape of mantle cell lymphoma.
Latest:
Do You Have the Right Tools?: How IT adoption can enhance your practiceTrue integration of cutting-edge care and timely translation of information from the bench to bedside requires an oncology practice to have knowledgeable physicians and a "toolbox of technology."
Latest:
Dr Desai on the Evolution of Divarasib in KRAS G12C-mutated CRCJayesh Desai, MBBS, FRACP, discusses the evolution of divarasib, highlighting the rationale for combining the KRAS G12C inhibitor with cetuximab in patients with advanced colorectal cancer harboring KRAS G12C mutations in a phase 1b study.
Latest:
Dr. Mehta on Stem Cell Transplant in Multiple MyelomaJayesh Mehta, MD, professor of medicine (hematology and oncology), Feinberg School of Medicine, discusses stem cell transplant in multiple myeloma.
Latest:
Jayshree Shah on the Safety and Efficacy of NilotinibJayshree Shah, from John Theurer Cancer Center, on the Safety and Efficacy of Nilotinib for Patients With CML
Latest:
Dr. Durand Discusses Treatment Options for Toxicities from Therapy in HER2+ Breast CancerJean-Bernard Durand, MD, professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center, discusses advice for community oncologists on managing patients that are experiencing symptoms from treatment for HER2-positive breast cancer.
Latest:
Dr. Bourhis on the OS Benefit of Xevinapant Plus Chemoradiotherapy in HNSCCJean Bourhis, MD, PhD, discusses the overall survival benefit of xevinapant plus chemoradiotherapy in head and neck squamous cell carcinoma.
Latest:
Dr. Hoffman-Censits Discusses the Future Treatment of Bladder CancerJean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.
Latest:
Dr. Jean Hurteau on Diagnosing Ovarian Clear Cell CarcinomaJean Hurteau, MD, professor, Division of Gynecologic Oncology at NorthShore University Health System, discusses the difficulties of diagnosing ovarian clear cell carcinoma. Hurteau says data for the diagnosis of the carcinoma is older, and is not relevant to contemporary diagnoses due to the fact that there were more mixed tumors previously than there are now.
Latest:
Dr. Grob on the Tolerability and Efficacy of Ipilimumab in MelanomaJean Jacques Grob, MD, PhD, professor of dermatology at the Hospital de la Timone, discusses the tolerability and efficacy of ipilimumab (Yervoy) for melanoma.
Latest:
Dr. Kiladjian on Improving Transfusion-Independence Rates With Momelotinib in MyelofibrosisJean-Jacques Kiladjian, MD, PhD, discusses the potential utility of momelotinib in improving transfusion-independence rates in myelofibrosis.
